A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

To join this study, people need to be adults between 18 and 65 years old and have been diagnosed with chronic hepatitis B. You must not have received treatment for hepatitis B before, or if you have, it must have been a long time ago (at least 6 months) and you are not currently taking any medicines for it. Your liver health will also be checked to make sure it meets specific levels for the study.

There are certain reasons why someone couldn't join. For example, if you also have other types of hepatitis (like A, C, D, or E) or HIV, or if you have any signs of serious liver problems like cirrhosis (scarring of the liver), severe liver damage, or a history of liver cancer. Also, if you've recently taken part in another medical study involving a new drug or device, you would not be able to join this one.

If you decide to take part in this study, you'll be assigned to take either the new drug, ALG-000184, or an existing medicine, tenofovir. You'll take one tablet by mouth once a day for 48 weeks. Neither you nor your study doctor will know which treatment you are on during this time. Throughout these 48 weeks, you will have regular visits to the clinic for medical check-ups, blood tests, and to discuss any side effects you might be experiencing. Some participants will also have a liver biopsy (a small sample of liver tissue taken) at the beginning and end of the main 48-week period.

After the first 48 weeks, you'll have the option to continue in the study for another 48 weeks, where everyone will receive ALG-000184. This means the total time you could be involved in the study is about 96 weeks (nearly two years). There will be regular follow-up appointments and tests throughout this entire period to monitor your health and how the treatment is working.